The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 1.28M shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 87.02% since April 4, 2016 and is uptrending. It has outperformed by 85.93% the S&P500.
The move comes after 6 months positive chart setup for the $1.99B company. It was reported on Nov, 4 by Barchart.com. We have $59.77 PT which if reached, will make NASDAQ:SRPT worth $1.01B more.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. RBC Capital Markets upgraded the stock to “Outperform” rating in Wednesday, August 26 report. Wedbush upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Tuesday, June 7 to “Outperform” rating. The firm has “Outperform” rating given on Monday, October 10 by Wedbush. The firm has “Underperform” rating by JMP Securities given on Wednesday, March 23. Piper Jaffray downgraded the shares of SRPT in a report on Friday, January 15 to “Neutral” rating. As per Monday, September 19, the company rating was upgraded by PiperJaffray. The rating was downgraded by William Blair on Thursday, April 21 to “Market Perform”. The stock has “Buy” rating given by Roth Capital on Wednesday, August 5. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Buy” rating by Bank of America on Friday, October 23. As per Friday, October 2, the company rating was maintained by Needham.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.32, from 0.84 in 2016Q1. The ratio is positive, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Gilder Gagnon Howe & Ltd holds 0.01% or 17,990 shares in its portfolio. Rhumbline Advisers owns 46,719 shares or 0% of their US portfolio. Public Employees Retirement Association Of Colorado holds 12,338 shares or 0% of its portfolio. Ghost Tree Capital Llc has 200,000 shares for 1.1% of their US portfolio. Teacher Retirement System Of Texas owns 6,034 shares or 0% of their US portfolio. Commonwealth Equity Service holds 15,828 shares or 0% of its portfolio. Us Bank & Trust De last reported 0% of its portfolio in the stock. Grp One Trading Limited Partnership holds 0.13% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 571,145 shares. Royal Bancorp Of Canada last reported 4,006 shares in the company. State Street last reported 3.09 million shares in the company. Moreover, First Allied Advisory has 0.01% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 12,800 shares. Quantitative Investment Management Limited Liability last reported 0.15% of its portfolio in the stock. Manufacturers Life Ins The holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 29,280 shares. Geduld E E, a New York-based fund reported 25,000 shares. Moreover, Jpmorgan Chase & Company has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 570 shares.
Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 8 sales for $8.94 million net activity. 24,352 shares with value of $1.22M were sold by Kaye Edward M. MD on Monday, September 19. Mahatme Sandesh had sold 30,000 shares worth $1.50M. 7,311 shares were sold by Ruff Shamim, worth $438,660. Shares for $465,200 were sold by Howton David T. Shares for $1.75M were sold by Aphale Jayant on Monday, September 19.
More important recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Profitconfidential.com which released: “Sarepta Therapeutics Inc: $40.00 Is Price Support on SRPT stock” on October 30, 2016, also Forbes.com published article titled: “Oversold Conditions For Sarepta Therapeutics (SRPT)”, Fool.com published: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) was released by: Finance.Yahoo.com and their article: “Sarepta Therapeutics reports 3Q loss” with publication date: October 27, 2016.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.